Form 4: Inovio Pharmaceuticals' Chief Medical Officer Receives Stock Options and Restricted Stock Units

Chief Medical Officer of Inovio Pharmaceuticals, Michael John Sumner, reports acquisition of stock options and restricted stock units.

Summary

• Michael John Sumner, Chief Medical Officer of Inovio Pharmaceuticals, filed a Form 4 on May 21, 2025.
• The report details the acquisition of 35,100 common stock options at an exercise price of $2.13, vesting in two tranches on May 20, 2027 and May 20, 2028.
• Additionally, 28,350 restricted stock units were granted, vesting in three equal installments on May 20, 2026, May 20, 2027, and May 20, 2028.
• The restricted stock units can be settled in shares of common stock, cash, or a combination of both.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, suggesting stability and alignment of interests. It's a neutral to slightly positive indicator.

Positives

• The grant of stock options and restricted stock units to the Chief Medical Officer aligns his interests with those of the shareholders.
• The vesting schedules encourage long-term commitment and performance.

Industry Context

Stock option and RSU grants are common practice to incentivize and retain key executives in the biotechnology industry.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Moderna and BioNTech also utilize stock options and RSUs to incentivize their leadership teams.
• The vesting schedules are typical, designed to encourage long-term commitment.

Stakeholder Impact

• Shareholders: The grants align management's interests with shareholder value.
• Employees: The grants can boost morale and incentivize performance.

Key Dates

Keywords

Form 4, Inovio Pharmaceuticals, Michael John Sumner, Stock Options, Restricted Stock Units, Beneficial Ownership, INO